You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
冠昊生物(300238.SZ)半年度淨利潤升41.03%至859.57萬元
格隆匯 08-22 17:19

格隆匯8月22日丨冠昊生物(300238.SZ)發佈2019年半年度報告,實現營業收入2.08億元,同比增長6.39%;歸屬於上市公司股東的淨利潤859.57萬元,同比增長41.03%;歸屬於上市公司股東的扣除非經常性損益後的淨虧損302.99萬元;基本每股收益0.03元。

影響公司損益的主要因素如下:

1. 報告期內,公司積極進行生物材料板塊及眼科市場營銷渠道優化和市場推廣,營業收入實現持續穩健增長,公司膜類及神經外科代理產品銷售收入同比增長21%;人工晶體產品因招投標價格及中美貿易戰關税影響,銷售量同比增長33%銷售收入同比基本持平,導致營業成本同比增長41.28%,一定程度上影響了公司利潤。

2. 報告期內,公司新藥產品本維莫德乳膏正在積極進行生產管理及營銷渠道建設,尚未實現正式銷售,本報告期虧損增加,影響歸屬上市公司股東淨利潤382.45萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account